Subsequent event - Additional Information (Details) - USD ($) |
Mar. 22, 2023 |
Mar. 19, 2023 |
Dec. 28, 2022 |
Jul. 02, 2022 |
Jan. 01, 2022 |
|---|---|---|---|---|---|
| Subsequent Event [Line Items] | |||||
| Common Stock, par value | $ 0.001 | ||||
| Preferred stock, shares authorized (in shares) | 2,000,000 | ||||
| Preferred stock, par value | $ 0.001 | ||||
| Series S Convertible Preferred Stock | |||||
| Subsequent Event [Line Items] | |||||
| Fair market value, shares issued | 100,000 | ||||
| Fair market value | $ 14,500,000 | ||||
| Asset Purchase Agreement | |||||
| Subsequent Event [Line Items] | |||||
| Common Stock, par value | $ 0.032 | ||||
| Subsequent Event | Soin Therapeutics L L C Member | |||||
| Subsequent Event [Line Items] | |||||
| BusinessCombinationDescription | Dr. Soin may convert up to three million dollars of value of the Series S Stock into shares of the Company's common stock commencing one year from the closing and may convert up to an additional $10 million of value of the Series S Stock into shares of the Company's common stock from and after the sooner of (y) the issuance by the FDA of New Drug Approval for low-dose naltrexone for treating pain or (z) 10 years from the closing. Further, during the 10-year period following the closing, Dr. Soin may convert up to an additional $17 million of value at a rate of five percent of the gross revenues that the Company receives in connection with sales or license revenue from the product.In connection with the merger, the Company employed an independent third-party firm to assess the fair value of the 100,000 shares of Series S Stock issued. The assessment determined that the fair market value of the Series S Stock was approximately $14.5 million, which was allocated to the intellectual property acquired. | ||||
| Subsequent Event | Soin Therapeutics L L C Member | Series S Convertible Preferred Stock | Stock Conversion1 | |||||
| Subsequent Event [Line Items] | |||||
| Conversion of stock, amount converted | $ 3,000,000 | ||||
| Subsequent Event | Soin Therapeutics L L C Member | Series S Convertible Preferred Stock | Stock Conversion2 | |||||
| Subsequent Event [Line Items] | |||||
| Conversion of stock, amount converted | 10,000,000 | ||||
| Subsequent Event | Soin Therapeutics L L C Member | Series S Convertible Preferred Stock | Stock Conversion3 | |||||
| Subsequent Event [Line Items] | |||||
| Conversion of stock, amount converted | $ 17,000,000 | ||||
| Subsequent Event | Sti Merger Sub Inc | Soin Therapeutics L L C Member | |||||
| Subsequent Event [Line Items] | |||||
| Common stock, shares outstanding, percentage | 4.99% | ||||
| Subsequent Event | Sti Merger Sub Inc | Soin Therapeutics L L C Member | Series S Convertible Preferred Stock | |||||
| Subsequent Event [Line Items] | |||||
| Preferred stock, shares authorized (in shares) | 200,000 | ||||
| Preferred stock, par value | $ 300.00 | ||||
| Stock issued during period, shares, acquisition | 100,000 | ||||
| Stock issued during period, value, acquisition | $ 13,000,000 | ||||
| Stock issued during period, additional value, acquisitions | 17,000,000 | ||||
| Busienss acquisition, shares issued, fair value | $ 30,000,000 | ||||
| Subsequent Event | Stock Purchase Agreement | ARCA and Subsidiaries Disposition | |||||
| Subsequent Event [Line Items] | |||||
| Reduction in liabilities | $ 17,600,000 | ||||
| Proceeds from subsidiaries | $ 24,000,000.0 | ||||
| Stock purchase agreement description | Each monthly payment is to be the greater of (a) $140,000 (or $100,000 for each January and February during the 15-year payment period) or (b) a monthly percentage-based payment, which is an amount calculated as follows: (i) 5% of the Subsidiaries’ aggregate gross revenues up to $2,000,000 for the relevant month, plus (ii) 4% of the Subsidiaries’ aggregate gross revenues between $2,000,000 and $3,000,000 for the relevant month, plus (iii) 3% of the Subsidiaries aggregate gross revenues over $3,000,000 for the relevant month | ||||
| Advance payment | $ 1,000,000 | ||||
| Subsequent Event | Securities Purchase Agreement | |||||
| Subsequent Event [Line Items] | |||||
| Common stock offering shares | 361,000 | ||||
| Common Stock, par value | $ 0.001 | ||||
| Common stock purchase price per share | $ 1.17 | ||||
| Proceeds from sale of common stock | $ 422,000 |